FOXC2 and Hepatic fibrosis: Further analysis showed that the expression of FOXC2, α-SMA, Col1A1, FN1and CTGF, and hepatocellular damage were also reduced following with AAV6-shFOXC2 treatment in CCl4 or BDL-induced liver fibrosis model (Fig. 8C, Fig. 8F-8G, Fig S6E, Fig. S9A, Fig. S9C-9D).